Procalcitonin for Diagnostics and Treatment Decisions in Pediatric Lower Respiratory Tract Infections
Philipp Baumann1, Gurli Baer1, Jessica Bonhoeffer2
1Department of Pediatric Infectious Diseases and Vaccinology, University of Basel Children's Hospital, Basel, Switzerland.
Insights
Pediatric lower respiratory tract infections cause 1.3 million child deaths annually. Procalcitonin (PCT) testing shows promise in guiding antibiotic use for pediatric LRTIs, reducing overuse and resistance.
Area of Science:
- Pediatrics
- Infectious Diseases
- Biomarkers
Background:
- Pediatric lower respiratory tract infections (LRTIs) remain a leading cause of mortality and morbidity, particularly in low- and middle-income countries.
- Current diagnostic methods for pneumonia lack specificity, failing to differentiate viral from bacterial causes, leading to widespread antibiotic overuse.
- This overuse contributes significantly to the growing global challenge of antibiotic resistance.
Purpose of the Study:
- To review current evidence on the utility of procalcitonin (PCT) for diagnosing pediatric LRTIs.
- To discuss the importance of establishing appropriate PCT thresholds for guiding antibiotic treatment decisions in children.
Main Methods:
- Systematic review of observational studies and randomized controlled trials.
- Analysis of procalcitonin (PCT) performance in differentiating bacterial from viral etiologies in pediatric LRTIs.
- Evaluation of PCT's impact on antibiotic prescribing patterns and outcomes.
Main Results:
- Procalcitonin (PCT) demonstrates potential as a biomarker to aid in distinguishing bacterial from viral LRTIs in children.
- Evidence suggests PCT can help reduce unnecessary antibiotic prescriptions for pediatric respiratory infections.
- Further research is needed to define optimal PCT cut-off values for clinical decision-making.
Conclusions:
- Procalcitonin (PCT)-guided diagnostics offer a promising strategy to optimize antibiotic use in pediatric lower respiratory tract infections.
- Implementing standardized PCT thresholds could mitigate antibiotic resistance and improve patient outcomes.
- Further validation studies are crucial for widespread clinical adoption.
Abstract:
Mortality and morbidity remain high in pediatric lower respiratory tract infections (LRTIs) despite progress in research and implementation of global diagnostic and treatment strategies in the last decade. Still, 120 million annual episodes of pneumonia affect children younger than 5 years each year leading to 1.3 million fatalities with the major burden of disease carried by low- and middle-income countries (95%). The definition of pneumonia is still challenging. Traditional diagnostic measures (i.e., chest radiographs, C-reactive protein) are unable to distinguish viral and from bacterial etiology. As a result, common antibiotic overuse contributes to growing antibiotic resistance. We present an overview of current evidence from observational and randomized controlled trials on a procalcitonin (PCT)-based diagnosis of pediatric LRTIs and discuss the need for an adequate PCT threshold for antibiotic treatment decision-making.
More Related Videos
06:15Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
05:31Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
00:51Synthesis and Functions of Calcitonin
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion